Lymphoma News

In this video, Brian T. Hill, MD, PhD, discusses results of the phase 2 PILOT study of lisocabtagene maraleucel as second-line therapy for relapsed/refractory diffuse large B-cell lymphoma.

SAN DIEGO — Infections are the main driver of mortality not related to disease relapse among individuals who received chimeric antigen receptor T cells, results of a meta-analysis presented at ASH Annual Meeting and Exhibition showed.

In this video, Brian T. Hill, MD, PhD, discusses important research on bispecific antibodies for the treatment of lymphoma presented at ASH Annual Meeting and Exhibition.

SAN DIEGO — Patients with relapsed large B-cell lymphoma who achieved a complete remission had a reduced relapse rate and improved PFS with autologous transplant, according to study findings presented at ASH Annual Meeting and Exposition.

Ibrutinib plus venetoclax demonstrated superior PFS and a higher complete response rate compared with ibrutinib plus placebo in patients with relapsed or refractory mantle cell lymphoma, according to study results.

SAN DIEGO — Individuals with private insurance that requires a signed agreement before receiving chimeric antigen receptor T cells had significant delays in treatment, study results presented at ASH Annual Meeting and Exposition showed.

In a special scientific session on race and science at ASH Annual Meeting an Exposition, Saad Z. Usmani, MD, MBA, FACP, FRCP, examined clinical trial inclusion from an investigator’s perspective.

SAN DIEGO — Significant racial and ethnic disparities exist in survival outcomes of adolescent and young adults with diffuse large B-cell lymphoma, according to study findings presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Individuals treated with first-generation Bruton tyrosine kinase inhibitors with preexisting cardiovascular disease had significantly higher odds of developing cardiovascular adverse events, study results showed.

SAN DIEGO — Subcutaneous time-limited mosunetuzumab exhibited “highly encouraging efficacy” among patients with newly diagnosed high-burden follicular lymphoma, according to researchers.